David Hastings appointed as CFO at Trevi Therapeutics, Nasdaq: TRVI, to lead financial strategy for growth.

Unusual Whales
2025.12.04 12:32
A skilled CFO from the biotech industry has been appointed to oversee financial strategy and support Trevi Therapeutics, Inc.'s growth phase in New Haven, Conn. The company, listed on Nasdaq as TRVI, specializes in developing the experimental drug Haduvio™. This strategic move was announced on Dec. 4, 2025.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer